MT-0169 is an investigative therapy that contains an antibody fragment targeting CD38 (a protein found in high levels on the surface of myeloma cells. It is fused to a Shiga-like toxin A-subunit (SLTA), a bacterial protein that, once inside malignant myeloma cells, irreversibly blocks the protein-making machinery of the cell and kills it.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.